Standout Papers

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer 2020 2026 2022 2024343
  1. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer (2020)
    Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology

Immediate Impact

10 by Nobel laureates 1 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
2 intermediate papers

Works of Christopher DiSimone being referenced

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
2020 Standout
Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
2019

Author Peers

Author Last Decade Papers Cites
Christopher DiSimone 268 167 108 142 10 470
A. De Jesus Acosta 299 150 74 118 9 513
Nicole Kelbick 256 134 157 94 9 511
J. Mazurka 119 169 167 85 15 484
H Nishii 138 119 176 83 15 481
Motohiko Shimizu 119 174 210 117 9 540
Lindsey E. Minion 170 90 141 50 15 436
Mark A. Glaire 315 134 149 71 15 574
Luke Freeman-Mills 194 185 172 63 7 482
Siel Olbrecht 203 86 121 71 13 470
Marina Asher 136 194 209 199 10 544

All Works

Loading papers...

Rankless by CCL
2026